Endocrinology · PANCE / PANRE

Hyperthyroidism (Graves Disease)

Autoimmune diffuse goiter driven by TSH-receptor stimulating antibodies; most common cause of overt hyperthyroidism.

Also known as: Graves disease, hyperthyroidism, thyrotoxicosis, TSI, diffuse toxic goiter

Overview

Autoimmune hyperthyroidism caused by stimulating antibodies (thyroid-stimulating immunoglobulins, TSI; also called TRAb) that bind and activate the TSH receptor, producing diffuse goiter, sustained thyroid hormone excess, and characteristic extrathyroidal manifestations (orbitopathy, dermopathy).

Epidemiology

Most common cause of hyperthyroidism in the United States. Female-to-male ratio ~5-10:1. Peak onset 30-50 years. Strong familial clustering and association with other autoimmune disease (T1DM, celiac, vitiligo, pernicious anemia, Addison disease).

Try two board-style Hyperthyroidism questions

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1EndocrineMedium
A 28-year-old woman reports heat intolerance, palpitations, and a 15-lb weight loss. Examination shows exophthalmos and a diffusely enlarged thyroid. Laboratory studies reveal an undetectable TSH, a markedly elevated free T4, and positive thyroid-stimulating immunoglobulin. Which of the following is the most appropriate initial management?
  • AMethimazole and propranolol
  • BTotal thyroidectomy
  • CLevothyroxine replacement
  • DRadioactive iodine ablation
Reveal answer & full explanation
Correct answer: A — Methimazole and propranolol
  • AMethimazole and propranolol
  • BTotal thyroidectomy
  • CLevothyroxine replacement
  • DRadioactive iodine ablation

Why Methimazole and propranolol is correct

  • Exophthalmos, diffuse goiter, suppressed TSH, high free T4, and positive thyroid-stimulating immunoglobulin establish Graves disease.
  • Initial therapy pairs a thionamide (methimazole), which blocks thyroid hormone synthesis, with a beta-blocker (propranolol) for adrenergic symptom control.
  • Patients are rendered euthyroid before any definitive therapy to avoid precipitating thyroid storm.

Why the others are wrong

  • Radioactive iodine ablation — a definitive option, but it requires a euthyroid state first and can transiently worsen hyperthyroidism and orbitopathy; choosing it now is right-diagnosis-wrong-step sequencing.
  • Total thyroidectomy — also definitive, but only after medical stabilization to euthyroid; the same sequencing trap.
  • Levothyroxine replacement — treats hypothyroidism and would worsen this hyperthyroid patient; an anchoring error on 'thyroid disease equals levothyroxine.'
Question 2EndocrineMedium
A 30-year-old woman at 10 weeks gestation has nausea, palpitations, and a diffusely enlarged thyroid. Free T4 is elevated, TSH is suppressed, and thyroid receptor antibody (TRAb) is positive at 1:320. She has no prior thyroid history. Which of the following antithyroid medications is most appropriate at this stage of pregnancy?
  • ARadioactive iodine
  • BPropylthiouracil
  • CMethimazole
  • DLevothyroxine
Reveal answer & full explanation
Correct answer: B — Propylthiouracil
  • ARadioactive iodine
  • BPropylthiouracil
  • CMethimazole
  • DLevothyroxine

Why Propylthiouracil is correct

  • Elevated free T4, suppressed TSH, a diffuse goiter, and a positive TRAb in a 10-week-pregnant patient establish Graves disease as the cause of gestational hyperthyroidism
  • During the first trimester (organogenesis, roughly weeks 6-10), the American Thyroid Association recommends propylthiouracil (PTU) over methimazole because methimazole is associated with a characteristic embryopathy (aplasia cutis, choanal/esophageal atresia, omphalocele)
  • Untreated Graves disease in pregnancy raises the risk of fetal loss, preterm delivery, and maternal heart failure, so antithyroid therapy is required rather than observation
  • Target the free T4 at or just above the upper limit of normal using the lowest effective dose

Why the others are wrong

  • Radioactive iodine — absolutely contraindicated in pregnancy and lactation because it ablates the fetal thyroid and delivers fetal radiation (confused-with nonpregnant Graves management)
  • Methimazole — effective but teratogenic during first-trimester organogenesis; it becomes the preferred agent only in the second and third trimesters, when PTU hepatotoxicity outweighs its benefit (right-drug-wrong-trimester)
  • Levothyroxine — treats hypothyroidism and would worsen this patient's thyrotoxicosis (right-concept-wrong-direction)

Additional high-yield points

  • Trimester-specific switch: change PTU to methimazole after the first trimester because prolonged PTU use carries rare but serious hepatotoxicity
  • TRAb crosses the placenta; titers above 3x the upper limit of normal predict fetal/neonatal hyperthyroidism, so monitor fetal heart rate and growth and check neonatal thyroid function at delivery
🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Hyperthyroidism (Graves Disease) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Female sex, age 30-50, family history of autoimmune thyroid disease
  • Smoking (strong risk factor for orbitopathy progression)
  • Iodine excess (amiodarone, iodinated contrast, kelp)
  • Postpartum state (1-12 months after delivery)
  • Stress, recent infection, high-dose biotin (assay interference)
  • Immune-checkpoint inhibitors and alemtuzumab

Pathophysiology

Loss of self-tolerance produces IgG antibodies (TRAb/TSI) that bind the TSH receptor and continuously stimulate follicular cells, driving hormone synthesis and gland hyperplasia. The same receptor (or shared antigens) on retro-orbital fibroblasts and pretibial fibroblasts produces orbitopathy and dermopathy. Excess T3/T4 increases beta-adrenergic receptor density and metabolic rate, explaining most clinical features.

Clinical presentation

Symptoms

  • Heat intolerance, sweating, palpitations, tremor, anxiety, insomnia
  • Unintentional weight loss despite increased appetite
  • Frequent loose stools, oligomenorrhea, proximal muscle weakness
  • Gritty, bulging eyes; diplopia; eyelid retraction (Graves orbitopathy)
  • Atrial fibrillation, especially in older adults (may be presenting feature)

Signs / physical exam

  • Diffuse, smooth, nontender goiter ± thyroid bruit
  • Warm moist skin, fine tremor of outstretched hands, brisk reflexes
  • Lid lag (von Graefe sign), stare, exophthalmos, periorbital edema, chemosis
  • Pretibial myxedema (raised, non-pitting, peau d'orange plaques over shins)
  • Thyroid acropachy (clubbing) — rare

Classic findings

Young woman with weight loss, palpitations, anxiety, diffuse goiter with bruit, and proptosis = Graves disease.

Differential diagnosis

  • Toxic multinodular goiter (Plummer disease) — Older patient, long-standing nontoxic goiter, heterogeneous uptake on RAIU with hot/cold areas; no orbitopathy
  • Toxic adenoma — Single autonomously functioning nodule; focal hot spot on RAIU with suppression of surrounding tissue
  • Subacute (de Quervain) thyroiditis — Painful tender thyroid after viral illness, elevated ESR, LOW RAIU; self-limited, transient hyperthyroid then hypothyroid phase
  • Painless / postpartum thyroiditis — Painless gland, transient thyrotoxicosis, LOW RAIU; often resolves spontaneously
  • Factitious thyrotoxicosis — Exogenous hormone ingestion; LOW thyroglobulin distinguishes from thyroiditis
  • Struma ovarii — Ovarian teratoma producing thyroid hormone; pelvic uptake on whole-body scan
  • TSH-secreting pituitary adenoma — Inappropriately normal/elevated TSH with elevated free T4/T3; pituitary mass on MRI; elevated alpha subunit
  • Amiodarone-induced thyrotoxicosis — Type 1: iodine-driven excess synthesis (preexisting nodular disease); Type 2: destructive thyroiditis. Color Doppler discriminates

Diagnostic workup

Diagnostic criteria

Suppressed TSH + elevated free T4 and/or T3 + positive TRAb, or diffuse uptake on RAIU scan. Orbitopathy or pretibial myxedema with biochemical thyrotoxicosis is sufficient even without antibody confirmation.

Labs

  • TSH (suppressed, <0.01 in overt disease) — most sensitive initial test
  • Free T4 and total T3 (elevated; T3-predominant toxicosis common in Graves)
  • TRAb (TSI) — highly specific; positive supports Graves and predicts orbitopathy/relapse
  • CBC (mild leukopenia and anemia common), LFTs (mild AST/ALT elevation baseline)
  • Pregnancy test in reproductive-age women (alters treatment choice)

Imaging

  • Radioactive iodine uptake and scan (RAIU/scan) — diffuse, homogeneous, ELEVATED uptake confirms Graves; differentiates from low-uptake thyroiditis and factitious
  • Thyroid ultrasound with color Doppler — hypervascular (thyroid inferno) in Graves; useful when RAIU contraindicated (pregnancy, lactation, recent iodine)
  • Orbital CT/MRI without contrast if moderate-to-severe orbitopathy (extraocular muscle enlargement sparing the tendons)

Diagnostic algorithm

CauseRAIUThyroglobulinTRAb / TSIKey feature
Graves diseaseElevated, diffuseElevatedPositiveOrbitopathy, bruit, diffuse goiter
Toxic multinodular goiterPatchy, heterogeneousElevatedNegativeOlder, nodular gland
Toxic adenomaFocal hot, rest suppressedElevatedNegativeSingle autonomous nodule
Subacute thyroiditisLowElevatedNegativePainful, post-viral, elevated ESR
Painless/postpartum thyroiditisLowElevatedNegativePainless, transient, postpartum
Factitious thyrotoxicosisLowLOWNegativeExogenous T4 ingestion
Differentiating causes of thyrotoxicosis by RAIU, thyroglobulin, and TRAb.

Treatment

First-line

  • Beta-blocker for adrenergic symptoms — propranolol 20-40 mg q6h (also blocks peripheral T4→T3 conversion at high dose) or atenolol/metoprolol; use cautiously in HF
  • Thionamide — methimazole 10-40 mg daily (first-line in non-pregnancy; longer half-life; less hepatotoxicity); propylthiouracil (PTU) preferred in 1st trimester pregnancy and thyroid storm; carbimazole (UK/EU)
  • Counsel on agranulocytosis (any sore throat or fever → stop drug and check CBC) and hepatotoxicity

Complications

  • Thyroid storm (life-threatening decompensation)
  • Atrial fibrillation, high-output heart failure, dilated cardiomyopathy
  • Osteoporosis and fracture (especially postmenopausal women)
  • Severe orbitopathy with vision loss
  • Thyrotoxic periodic paralysis (Asian male predominance)
  • Agranulocytosis or hepatotoxicity from thionamides; transient or permanent hypoparathyroidism after surgery

PANCE pearls

  • TRAb (TSI) is the most specific antibody for Graves disease and helps predict relapse after thionamide withdrawal.
  • PTU is preferred only in the FIRST trimester of pregnancy and in thyroid storm; methimazole is first-line otherwise because of better hepatic safety.
  • Avoid radioactive iodine in moderate-to-severe active orbitopathy — it can precipitate flare. Use thyroidectomy or thionamides instead.
  • Always check beta-hCG before RAI ablation in reproductive-age women.
  • Thyrotoxic periodic paralysis: sudden hypokalemic paralysis in an Asian man with new hyperthyroidism — treat with potassium and beta-blocker, then definitive thyroid therapy.

References

  • ATA 2016 — 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (Ross et al., Thyroid 2016)
  • ATA/AACE Pregnancy 2017 — 2017 Guidelines of the ATA for Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (Alexander et al., Thyroid 2017)
  • EUGOGO 2021 — The 2021 European Group on Graves' Orbitopathy (EUGOGO) Clinical Practice Guidelines (Bartalena et al., Eur Thyroid J 2021)

Practice Endocrinology questions on FirstPassPA

Turn this outline into retention. 6,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.